Inspire Medical Systems, Inc. · NYSE:INSP

Inspire Medical Systems — JP Morgan Healthcare Conference 2023

21 slides from Inspire Medical Systems's conference presentation, Jan 9, 2023

Slide 1: Inspire Medical Systems, Inc. JP Morgan Healthcare Conference
1 Inspire Medical Systems, Inc. JP Morgan Healthcare Conference January 9, 2023 NYSE: INSP
Slide 2: Disclaimer
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statement
Slide 3: Obstructive Sleep Apnea is a Serious and Chronic Disease
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Obstructive Sleep Apnea is a Serious and Chronic Disease OSA is Caused by a Blocked or Partially Blocked Airway • Blockage prevents airflow to the lungs • Results in repeated arousals and oxygen de-saturations • Severity of sle
Slide 4: Current Treatment Options, Such as CPAP and Invasive Surgery, Have Significant Limitations
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Current Treatment Options, Such as CPAP and Invasive Surgery, Have Significant Limitations Ina Uvulopalatopharyngoplasty (UPPP) Maxillomandibular Advancement (MMA) • Several variations of sleep surgery • Success rates vary wide
Slide 5: Inspire Therapy is a Proven Solution for Patients with OSA
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Inspire Therapy is a Proven Solution for Patients with OSA Inspire System 1 2 3 Three implanted devices and patient remote: Pressure sensing lead: detects when the patient is attempting to breathe Neurostimulator: houses the el
Slide 6: 2022 New Product Deliveries
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL 2022 New Product Deliveries SleepSync™ Patient Management System • Remote to app to cloud connectivity • Enables patient management remotely & by exception • Leveraged existing Inspire cloud & remote infrastructure Silicone Lea
Slide 7: Unified Patient Management Platform
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Unified Patient Management Platform 7 Inspire SleepSync™ InspireSleep App Programmer Remote Inspire Cloud Inspire IV/V Stimulator
Slide 8: Continuous Data Collection and Outcomes Monitoring
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Continuous Data Collection and Outcomes Monitoring • Collect real-world, international outcomes data • Eligibility – ALL patients receiving Inspire therapy • ADHERE Registry - 4,000+ enrollments at 62 medical centers with enrol
Slide 9: Inspire Patient Experience Report - Safety
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL 96.0% 96.5% 97.0% 97.5% 98.0% 98.5% 99.0% 99.5% 100.0% 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 Cu m ul at iv e Su rv iv al P er ce nt ag e Months After Implant 2018 2020 2019 2021 2022 Inspire Patient Experience
Slide 10: Inspire focus is to maintain strong Patient Outcomes
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Inspire focus is to maintain strong Patient Outcomes 33.0 7.8 10.2 0 5 10 15 20 25 30 35 Baseline (n=1,963) 6-mo Titration Study (n=1,852) 12-mo All Night Study (n=890) M ed ia n AH I ( ev en ts /h ou r) Apnea Hypopnea Index (A
Slide 11: Quarterly Revenue
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL $16.3 $18.0 $20.9 $26.9 $21.3 $12.2 $35.8 $46.0 $40.4 $53.0 $61.7 $78.4 $69.4 $91.4 $109.2 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 E4Q22 ____________________ Quarterly amounts are unaudited Qu
Slide 12: Annual Revenue and Gross Margin
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL $28.6 $50.6 $82.1 $115.4 $233.4 2017 2018 2019 2020 2021 2022 2017 – 2021 CAGR: 69% Annual Revenue and Gross Margin ($ in millions) Annual Gross Margin 78.9% 80.1% 83.4% 84.7% 85.7% Guidance 83 – 85% 12 2022 Guidance: • FY2022
Slide 13: Steady Cadence of New Center Adds
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Steady Cadence of New Center Adds 7 10 12 18 15 15 15 22 20 19 21 33 28 15 42 55 47 63 68 81 73 51 58 61 0 100 200 300 400 500 600 700 800 900 1000 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q
Slide 14: DTC Program: Strategic Pillars
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL DTC Program: Strategic Pillars #3: Convert to Appointment #1: Drive Efficient Awareness #2: Educate & Segment IS.com #4: Support Inspire implant and longitudinal follow-up National DTC campaign >78k physician contacts in 2022 1
Slide 15: Upcoming Catalysts
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL 2024 2025 & Beyond 2023 • Neurostimulator replacements of initial commercial units • ~11-year battery life • Inspire V launch in the U.S. • Sensor incorporated inside the IPG • Removes need for pressure sensing lead  Pediatric
Slide 16: Our Growth Strategy
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Our Growth Strategy • Ensure strong and consistent patient outcomes globally through planned and controlled market expansion and robust physician training • Strong investments in the Inspire technology to further improve the pa
Slide 19: Company Overview
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL Company Overview • Inspire is the first and only FDA-approved neurostimulation technology for Obstructive Sleep Apnea (OSA) with significant first-mover advantage • Innovative, closed-loop, primary cell solution with ~11-year b
Slide 20: Strong Management Team
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL 30+ Years of Experience incl. 16 years at Inspire Randy Ban Chief Commercial Officer 25+ Years of Experience incl. 9 years at Inspire 25+ Years of Experience Incl. 14 years at Inspire 20+ Years of Experience Incl. 3 years at In
Slide 21: A Strong Market Opportunity Exists for an Alternative to CPAP
© Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL A Strong Market Opportunity Exists for an Alternative to CPAP that is Effective and Minimally Invasive  Sleep apnea affects +100 million people worldwide1  Approximately 17 million individuals in the U.S. with moderate to sev

Inspire Medical Systems — JP Morgan Healthcare Conference 2023 on 6ix

Inspire Medical Systems — JP Morgan Healthcare Conference 2023

Slide 1: Inspire Medical Systems, Inc. JP Morgan Healthcare Conference

Slide 2: Disclaimer

Slide 3: Obstructive Sleep Apnea is a Serious and Chronic Disease

Slide 4: Current Treatment Options, Such as CPAP and Invasive Surgery, Have Significant Limitations

Slide 5: Inspire Therapy is a Proven Solution for Patients with OSA

Slide 6: 2022 New Product Deliveries

Slide 7: Unified Patient Management Platform

Slide 8: Continuous Data Collection and Outcomes Monitoring

Slide 9: Inspire Patient Experience Report - Safety

Slide 10: Inspire focus is to maintain strong Patient Outcomes

Slide 11: Quarterly Revenue

Slide 12: Annual Revenue and Gross Margin

Slide 13: Steady Cadence of New Center Adds

Slide 14: DTC Program: Strategic Pillars

Slide 15: Upcoming Catalysts

Slide 16: Our Growth Strategy

Slide 17: INSPIRE ™

Slide 18: Appendix

Slide 19: Company Overview

Slide 20: Strong Management Team

Slide 21: A Strong Market Opportunity Exists for an Alternative to CPAP